Dawn Baker

1.1k total citations · 1 hit paper
8 papers, 835 citations indexed

About

Dawn Baker is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Dawn Baker has authored 8 papers receiving a total of 835 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 5 papers in Cancer Research and 2 papers in Oncology. Recurrent topics in Dawn Baker's work include Fibroblast Growth Factor Research (5 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Angiogenesis and VEGF in Cancer (3 papers). Dawn Baker is often cited by papers focused on Fibroblast Growth Factor Research (5 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Angiogenesis and VEGF in Cancer (3 papers). Dawn Baker collaborates with scholars based in United Kingdom, United States and Czechia. Dawn Baker's co-authors include Elaine Kilgour, Claire Rooney, Lorraine Mooney, Katherine Al-Kadhimi, Paul R. Gavine, Tanya Coleman, Andrew P. Thomas, Teresa Klinowska, Sarah Beck and Martine J. Mellor and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Dawn Baker

8 papers receiving 821 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family

2012 415 citations Paul R. Gavine, Lorraine Mooney et al. Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dawn Baker United Kingdom	8	623	233	157	157	58	8	835
I‐Mei Siu United States	16	494 0.8×	160 0.7×	121 0.8×	190 1.2×	60 1.0×	22	823
Linda M. Murphy United States	12	686 1.1×	334 1.4×	252 1.6×	201 1.3×	83 1.4×	14	1.1k
Carolina Zandueta Spain	17	443 0.7×	305 1.3×	168 1.1×	281 1.8×	54 0.9×	25	833
Khoi Chu United States	15	432 0.7×	468 2.0×	218 1.4×	188 1.2×	95 1.6×	22	869
Colin Cooper United Kingdom	17	639 1.0×	208 0.9×	332 2.1×	299 1.9×	78 1.3×	28	1.1k
Madelon Paauwe Netherlands	13	456 0.7×	380 1.6×	114 0.7×	261 1.7×	50 0.9×	16	805
Michele Massimino Italy	22	496 0.8×	297 1.3×	131 0.8×	249 1.6×	29 0.5×	64	1.2k
Gvantsa Kharaishvili Czechia	18	404 0.6×	347 1.5×	153 1.0×	221 1.4×	107 1.8×	26	776
Thomas Kryza Australia	16	256 0.4×	268 1.2×	116 0.7×	160 1.0×	57 1.0×	33	657
Femke Hillen Netherlands	8	531 0.9×	349 1.5×	114 0.7×	321 2.0×	64 1.1×	9	882

Countries citing papers authored by Dawn Baker

Since Specialization

Citations

This map shows the geographic impact of Dawn Baker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dawn Baker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dawn Baker more than expected).

Fields of papers citing papers by Dawn Baker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dawn Baker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dawn Baker. The network helps show where Dawn Baker may publish in the future.

Co-authorship network of co-authors of Dawn Baker

This figure shows the co-authorship network connecting the top 25 collaborators of Dawn Baker. A scholar is included among the top collaborators of Dawn Baker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dawn Baker. Dawn Baker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Delpuech, Oona, Claire Rooney, Lorraine Mooney, et al.. (2016). Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547. Molecular Cancer Therapeutics. 15(11). 2802–2813. 18 indexed citations

2.

Rooney, Claire, Catherine Geh, Victoria Williams, et al.. (2016). Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon. PLoS ONE. 11(2). e0149628–e0149628. 21 indexed citations

3.

Kilgour, Elaine, David Ferry, Matilde Saggese, et al.. (2014). Exploratory biomarker analysis of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors.. Journal of Clinical Oncology. 32(15_suppl). 11010–11010. 15 indexed citations

4.

Smith, Neil R., Dawn Baker, Matthew R. Farren, et al.. (2013). Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy. Clinical Cancer Research. 19(24). 6943–6956. 111 indexed citations

5.

Jenkins, David W., Sarah J. Ross, Margaret H. Veldman-Jones, et al.. (2012). MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo. Molecular Cancer Therapeutics. 11(8). 1650–1660. 47 indexed citations

6.

Gavine, Paul R., Lorraine Mooney, Elaine Kilgour, et al.. (2012). AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family. Cancer Research. 72(8). 2045–2056. 415 indexed citations breakdown →

7.

Gavine, Paul R., Lorraine Mooney, Elaine Kilgour, et al.. (2011). Abstract 3568: Characterization of AZD4547: An orally bioavailable, potent and selective inhibitor of FGFR tyrosine kinases 1, 2 and 3. Cancer Research. 71(8_Supplement). 3568–3568. 11 indexed citations

8.

Smith, Neil R., Dawn Baker, Neil H. James, et al.. (2010). Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers. Clinical Cancer Research. 16(14). 3548–3561. 197 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact